Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09QVV
|
|||
| Former ID |
DAP000114
|
|||
| Drug Name |
Vincristine
|
|||
| Synonyms |
LCR; Leurocristine; Marqibo; Oncovine; Tecnocris; VCR; VIN; Vincasar; Vincristina; Vincristinum; Vincrstine; Vincrystine; Vinkristin; Indole alkaloid; Liposomal Vincristine; Onco TCS; Vincristina [DCIT]; Oncovin (TN); Tecnocris (TN); Vincristine (INN); Vincristine [INN:BAN]; Vincristinum [INN-Latin]; Lilly37231 (1:1 sulfate salt); Oncovin (1:1 sulfate salt); Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Z-D-Val-Lys(Z)-OH; 22-Oxovincaleukoblastine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute lymphoblastic leukaemia [ICD-11: 2A85; ICD-10: C85.1, C88.7] | Approved | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Mayne Pharma Limited
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C46H56N4O10
|
|||
| Canonical SMILES |
CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
|
|||
| InChI |
1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
|
|||
| InChIKey |
OGWKCGZFUXNPDA-XQKSVPLYSA-N
|
|||
| CAS Number |
CAS 57-22-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9413, 598397, 8153716, 11431056, 14717665, 14889382, 26757081, 29224994, 46507033, 48424284, 49854447, 53788615, 56312035, 56314177, 57323093, 74979043, 92309095, 96025362, 104029594, 104310773, 124892473, 124892475, 126687244, 127301091, 127301092, 127301093, 127301094, 127301095, 127301096, 127301097, 127301098, 127301099, 127301100, 127301101, 127301102, 127301103, 127301104, 127301105, 127301106, 127301107, 127301108, 127301109, 127301110, 127301111, 127301112, 127301113, 127301114, 127301115, 127301116, 127301117
|
|||
| ChEBI ID |
CHEBI:28445
|
|||
| ADReCS Drug ID | BADD_D02360 ; BADD_D02361 | |||
| SuperDrug ATC ID |
L01CA02
|
|||
| SuperDrug CAS ID |
cas=000057227
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tubulin beta (TUBB) | Target Info | Modulator | [3] |
| KEGG Pathway | Phagosome | |||
| Gap junction | ||||
| Pathogenic Escherichia coli infection | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| EGFR1 Signaling Pathway | ||||
| Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
| Huntington disease | ||||
| Reactome | Regulation of PLK1 Activity at G2/M Transition | |||
| Loss of Nlp from mitotic centrosomes | ||||
| Recruitment of mitotic centrosome proteins and complexes | ||||
| Loss of proteins required for interphase microtubule organization?from the centrosome | ||||
| Anchoring of the basal body to the plasma membrane | ||||
| WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | |||
| Pathogenic Escherichia coli infection | ||||
| Mitotic G2-G2/M phases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6785). | |||
| REF 2 | Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP. Biochemistry. 2007 Dec 25;46(51):14899-906. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.